SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES
    55.
    发明申请
    SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES 审中-公开
    取代的萘啶酮及其作为药物的用途

    公开(公告)号:US20110201608A1

    公开(公告)日:2011-08-18

    申请号:US13057288

    申请日:2009-07-23

    摘要: The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 denotes a group A selected from among —O—R3, —NR3R4, —CR3R4R5, -(ethyne)-R3, —S—R3, —SO—R3 and SO2—R3 or R1 denotes a group B selected from among C6-10-aryl, five- to ten-membered, mono- or bicyclic heteroaryl with 1-3 heteroatoms selected independently of one another from among N, O and S; while this heteroaryl is linked to the structure according to formula 1 via either a C atom or an N atom, three- to ten-membered, mono- or bicyclic, saturated or partially saturated heterocyclic group with 1-3 heteroatoms selected independently of one another from among N, O and S, while this heterocyclic group is linked to the structure according to formula 1 via either a C atom or an N atom, and 5- to 11-membered spiro group which may optionally contain 1, 2 or 3 heteroatoms selected independently of one another from among N, O and S, while this spiro group is linked to the structure according to formula 1 via either a C atom or an N atom, while this group B may optionally be substituted as described in claim 1 and wherein R2 is and R3, R4, R5, R6, R6′, R7, R8, R9, R10, V, n and m may have the meanings given in claim 1, as well as pharmaceutical compositions containing these compounds.

    摘要翻译: 本发明涉及式1的新取代的萘啶,以及其药学上可接受的盐,非对映异构体,对映异构体,外消旋体,水合物或溶剂化物,其中R1表示选自-O-R3,-NR3R4,-CR3R4R5, (乙炔)-R 3,-S-R 3,-SO-R 3和SO 2 -R 3或R 1表示选自C 6-10 - 芳基,5至10元,单 - 或双环杂芳基和1-3 从N,O和S中彼此独立地选择的杂原子; 而该杂芳基通过C原子或N原子连接到根据式1的结构,具有1-3个互相独立选择的杂原子的三至十元,单环或二环,饱和或部分饱和的杂环基 N,O和S中的至少一个,而该杂环基通过C原子或N原子与根据式1的结构连接,并且可以任选地含有1,2或3个杂原子的5至11元螺环 N,O和S彼此独立地选择,而该螺环通过C原子或N原子连接到根据式1的结构,而该基团B可以任选地被如权利要求1和 其中R2是和R3,R4,R5,R6,R6',R7,R8,R9,R10,V,n和m可以具有权利要求1中给出的含义,以及含有这些化合物的药物组合物。